Avandia rosiglitazone: Post-marketing study data

A retrospective analysis of 28,938 patients treated with either Avandia rosiglitazone or Actos pioglitazone between 2001-05 showed no significant difference between treatment

Read the full 227 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE